SCHEMBL323401

SCHEMBL323401

O=C(OCc1ccc(F)cc1F)N1C=Cc2ccccc2C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL9 O00512 1/20 0.40
CTNNB1 P35222 1/20 0.40
ALDH1A1 P00352 3/20 0.38
IDO1 P14902 2/20 0.38
AGXT P21549 2/20 0.38
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
TAS1R2 Q8TE23 1/20 0.38
MAOB P27338 1/20 0.38
PTGER1 P34995 1/20 0.37
PTGDR2 Q9Y5Y4 4/20 0.36
TDP1 Q9NUW8 1/20 0.35
KDM5A P29375 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
KDM5B Q9UGL1 1/20 0.35
DPP8 Q6V1X1 1/20 0.35
DPP9 Q86TI2 1/20 0.35
GSK3B P49841 1/20 0.35
BACE1 P56817 1/20 0.35
GRIN2B Q13224 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL323140 0.91 MMP2 (0.42) TAS1R3TAS1R1TAS1R2PTGDR2HDAC3
SCHEMBL323574 0.88 GRIN2B (0.41) ALDH1A1GRIN2BL3MBTL1
SCHEMBL323904 0.88 ALDH1A1 (0.37) ALDH1A1TAS1R3TAS1R1TAS1R2PTGDR2
SCHEMBL324380 0.84 P2RX4 (0.42) PTGDR2GRIN2BL3MBTL1HDAC3
SCHEMBL323355 0.84 HCAR2 (0.43) MAOBPTGDR2GRIN2B
SCHEMBL324441 0.83 HSD17B3 (0.43) PTGER1PTGDR2TDP1HDAC3
SCHEMBL324997 0.82 F13A1 (0.39) ALDH1A1PTGDR2GRIN2BL3MBTL1HDAC3
SCHEMBL323819 0.81 MMP1 (0.39) ALDH1A1PTGDR2TDP1GRIN2BALOX15
SCHEMBL323930 0.81 HSD17B3 (0.46) TDP1L3MBTL1HDAC3
SCHEMBL324992 0.81 NPSR1 (0.37) PTGDR2KDM5AKDM4CKDM5BGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9255090-B2 Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators ACTELION PHARMACEUTICALS LTD. (CH) 2016-02-09 US disclosed
US-20150252036-A1 Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators IDORSIA PHARMACEUTICALS LTD (CH) 2015-09-10 US disclosed
EP-2794563-A1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2014-10-29 EP disclosed
WO-2013093842-A1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2013-06-27 WO disclosed
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252036-A1 Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators PTGDR, PTGER1, PTGDR2 BCL9 1148/4885CTNNB1 3544/4885ALDH1A1 2277/4885
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 BCL9 1599/4885CTNNB1 3202/4885ALDH1A1 2057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.